leisure time -WSS

leisure time

author：focus 2025-09-30 11:58:28 - browse：24267

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： NVIDIA and Google execs on the future of AI and drug discovery

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

How generative AI ratchets up security threats for health systems

Solving academic medical centers' existential crisis

Investment in vaccine development is lagging, report finds

Case highlights the risks of experimental stem cell therapy

White House pharmacy plagued with problems, investigation finds

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Supreme Court strikes down use of affirmative action

Humana’s losses in Medicare Advantage tank its stock

Walensky prepares to leave CDC — and Congress — behind

Glen Campbell's doctor discusses his public struggle with Alzheimer's

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Hollywood unions extend contract negotiations for actors

Second House panel advances two

Wikipedia

It's time to retire 'poor historian' from clinicians' vocabularies

Medicare Advantage insurers face 0.2% cut to 2025 payments

New clues to why women have higher risk of autoimmune disorders

Zyn nicotine pouches become unlikely player in latest culture war

Bernie Sanders is gearing up to subpoena pharma CEOs

FTC sues over Novant Health acquisition of two N.C. hospitals

focus

hotspot

focus

hotspot